



OPEN

SUBJECT AREAS:

TRANSLATIONAL
RESEARCH

MEDICAL RESEARCH

Received

26 August 2014

Accepted

2 February 2015

Published

8 April 2015

Correspondence and
requests for materials
should be addressed to
J.L. (jliu@gzhmu.edu.
cn)

* These authors
contributed equally to
this work.

Gambogic acid induces apoptosis in diffuse large B-cell lymphoma cells *via* inducing proteasome inhibition

Xianping Shi^{1*}, Xiaoying Lan^{1*}, Xin Chen¹, Chong Zhao¹, Xiaofen Li¹, Shouting Liu¹, Hongbiao Huang¹, Ningning Liu^{1,2}, Dan Zang¹, Yuning Liao¹, Peiquan Zhang¹, Xuejun Wang^{1,3} & Jinbao Liu¹

¹State Key Lab of Respiratory Disease, Protein Modification and Degradation Lab, Departments of Pathophysiology and Biochemistry, Guangzhou Medical University, Guangdong 510182, China, ²Guangzhou Research Institute of Cardiovascular Disease, the Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong 510260, People's Republic of China, ³Division of Basic Biomedical Sciences, Sanford School of Medicine of the University of South Dakota, Vermillion, South Dakota 57069, USA.

Resistance to chemotherapy is a great challenge to improving the survival of patients with diffuse large B-cell lymphoma (DLBCL), especially those with activated B-cell-like DLBCL (ABC-DLBCL). Therefore it is urgent to search for novel agents for the treatment of DLBCL. Gambogic acid (GA), a small molecule derived from Chinese herb gamboges, has been approved for Phase II clinical trial for cancer therapy by Chinese FDA. In the present study, we investigated the effect of GA on cell survival and apoptosis in DLBCL cells including both GCB- and ABC-DLBCL cells. We found that GA induced growth inhibition and apoptosis of both GCB- and ABC-DLBCL cells *in vitro* and *in vivo*, which is associated with proteasome malfunction. These findings provide significant pre-clinical evidence for potential usage of GA in DLBCL therapy particularly in ABC-DLBCL treatment.

Diffuse large B-cell lymphoma (DLBCL), an aggressive form of non-Hodgkin's lymphoma (NHL), accounts for approximately 30%–40% of all NHL¹. There are three subcategories in DLBCL: activated B-cell-like DLBCL (ABC-DLBCL), germinal center B-cell-like DLBCL (GCB-DLBCL) and primary mediastinal DLBCL (PMBCL)^{2,3}. These subtypes are characterized by distinct differences in survival, chemoresponsiveness, as well as dependence on signaling pathways, especially the nuclear factor- κ B (NF- κ B) pathway. In particular, the ABC-DLBCL subtype, which is NF- κ B-dependent, appears to have the worst prognosis among the three subtypes^{4–6}. Patients with the ABC-DLBCL tend to have the poorest 5-year survival rate (16%), compared to GCB-DLBCL (76%) and PMBCL (64%)⁷. Treatment for DLBCL has been improved over the last decade, especially with the development of Rituximab, an anti-CD20 monoclonal antibody, in combination with CHOP (C_{yclo}phosphamide, H_{ydroxy}rubin, O_{ncovin}, and P_{rednisone}) therapy program^{8,9}. Unfortunately, adverse events including bronchospasm, hypotension, cardiac arrhythmias and renal failure occur during the therapy. Furthermore, at least 25–30% of patients experience disease recurrence and patients with the ABC-DLBCL subtype is much more resistant to current treatment regimens^{10,11}. Resistance to the Rituximab-CHOP (R-CHOP) therapy program develops over time and is becoming an emerging problem for DLBCL treatment. Therefore, the development of innovative therapies and identification of more effective drugs for DLBCL are clearly needed.

Gambogic acid (GA), a small molecule extracted from the traditional Chinese medicine gamboges¹², has been approved by Chinese FDA for phase II clinical trial in solid tumor therapy^{13,14}. Unlike other chemotherapeutics, GA has very low toxicity to the hematopoietic system^{15,16}. Several molecular targets of GA have been proposed^{17,18}. Most recently, we have reported that GA is a novel tissue-specific proteasome inhibitor, with potency comparable to bortezomib but much less toxicity¹⁹. Although proteasome inhibitors such as carfilzomib have been reported to induce cell death in DLBCL cells combining with HDAC (histone deacetylase) inhibitors²⁰, the effect of GA on DLBCL remains unknown.

Here, we investigated the effects of GA in DLBCL cell lines and in mouse models. Strikingly, GA displays pronounced antineoplastic activity in both GCB- and ABC-DLBCL cells and in *in vivo* DLBCL xenograft models.



Results

GA inhibits cell proliferation in both GCB-DLBCL and ABC-DLBCL cells. SU-DHL-4 (GCB-DLBCL) cells are sensitive, while SU-DHL-2 (ABC-DLBCL) cells are very resistant, to R-CHOP therapy^{3,21}. To investigate the effect of GA on the growth of DLBCL cells, SU-DHL-4 and SU-DHL-2 cells were treated with GA *in vitro* for 48 hours and cell viability was detected by MTS assay. As shown in Figure 1A, GA dose-dependently decreased the cell viability in SU-DHL-4 and SU-DHL-2 cells with IC₅₀ values of 0.16 μ M and 0.30 μ M, respectively.

We next analyzed the kinetics of the capacity of GA to inhibit cell growth in GCB- and ABC-DLBCL cell lines. SU-DHL-4 and SU-DHL-2 cells were exposed to GA followed by trypan blue exclusion staining, a time- and dose-dependent decreasing proportion of total cells was observed by recording the total number of both trypan blue-positive and -negative cells (Figure 1B).

GA induces cell death in both GCB- and ABC-DLBCL cell lines. We then examined the ability of GA to induce cell death in GCB- and ABC-DLBCL cell lines. SU-DHL-4 and SU-DHL-2 cells were treated with escalating concentrations of GA, followed by recording the PI-positive cells with fluorescence microscopy (Figure 1C) or by Annexin V/PI staining coupled with flow cytometry (Figure 1D). A dose-dependent cell death was observed.

GA induces caspase activation in both GCB- and ABC-DLBCL cells. SU-DHL-4 and SU-DHL-2 cells were then exposed to GA, followed by measurement of apoptosis-associated proteins. The cleavage of PARP was detected with western blot analysis in a dose- and time-dependent manner. Simultaneously, GA treatment led to a decrease of the precursor forms of caspase-3, -8 and -9, as well as an increase of the active forms of caspase-3, -8 and -9, matching the pattern of PARP cleavage (Figure 2A). These data suggest that GA trigger DLBCL cell apoptosis likely *via* caspase activation.

It is well known that mitochondria are the regulating center of apoptosis. Release of cytochrome C and AIF from mitochondria to the cytoplasm is recognized as an indicator of the early stage of apoptosis²². As shown in Figure 2B, the integrity of mitochondrial membranes was decreased in both SU-DHL-4 and SU-DHL-2 cells after GA treatment. Moreover, after GA treatment, elevated levels of cytosolic cytochrome C and AIF, and reciprocally decreased levels of mitochondrial cytochrome C and AIF, were detected in a time-dependent manner in these two cell lines (Figure 2C).

To further understand the mechanism of GA-induced apoptosis, the effects of GA on the expression of other apoptosis-related proteins were measured. As shown in Figure 2D, GA decreased the level of anti-apoptotic proteins XIAP and Survivin in both SU-DHL-4 and SU-DHL-2 cells. The level of proapoptotic protein Bax increased in both cell lines, with less remarkable changes in the expression of Bcl-2. We also found that the level of anti-apoptotic protein myeloid cell leukaemia-1 (Mcl-1) was increased in the case of short-term or low-dose of GA treatment, but was still decreased with increasing doses and extension of time. We further observed that administration of pan-caspase inhibitor z-VAD-fmk prevented most GA-mediated decreases of XIAP but not Mcl-1 (Figure 2E). These results demonstrate that GA-induced caspase activation is required for the downregulation of anti-apoptotic protein XIAP.

GA inhibits proteasome function in GCB- and ABC-DLBCL cells. As reported in other cancer cells^{19,44}, we found that GA dose- and time-dependently inhibited proteasome function in both GCB- and ABC-DLBCL cell lines. We first examined the proteasome peptidase activities in cultured GCB- and ABC-DLBCL cells. We found that GA dose-dependently inhibited the chymotrypsin-like activities in SU-DHL-4 and SU-DHL-2 cells (Figure 3A). Furthermore, GA induced accumulation of ubiquitinated proteins (Ubs) and

proteasome substrate proteins p27 and p21 in SU-DHL-4 and SU-DHL-2 cells (Figure 3B). Mcl-1 can be degraded by the proteasome. Also corroborating a proteasome inhibition action by GA, Mcl-1 protein levels were discernibly increased in cells with low dose or short time GA treatment (Figure 2D, 2E). These results confirm that GA at a low concentration can significantly inhibit proteasome function in these DLBCL cells, associated with induction of cytotoxicity (Figure 1).

GA downregulates the protein but not mRNA levels of some of the NF- κ B target genes. We also found that GA treatment up-regulates the expression of I κ B α which is an important proteasome substrate protein (Figure 3C). Further results showed that GA down-regulated the total and phosphorylation levels of the p65 subunit of NF- κ B proteins in SU-DHL-4 and SU-DHL-2 cells in both a dose- and time-dependent manner (Figure 3C). To further determine the role of NF- κ B inhibition in the proapoptotic activity of GA, we analyzed the effect of this compound on the protein and mRNA levels of some of the NF- κ B target genes involved in cell survival, including IAP1, IAP-2, Bcl-x and Bfl-1. The results showed that GA down-regulated IAP1, IAP-2, Bcl-x and Bfl-1 protein expression to some extent during the long-term or high-dose GA treatment (Fig. 3C); however, real time PCR analyses failed to detect significant decreases in the mRNA level of these genes (supplementary data).

As NF- κ B should enter the nucleus to exert its activities²³, we then examined the translocation of NF- κ B into the nucleus. As shown in Figure 3D, neither PS341 nor various doses of GA consistently decreased the nuclear presence of the NF- κ B p65 subunit in SU-DHL-2 cells.

GA-mediated proteasome inhibition is required for caspase activation. Next we investigated whether GA-mediated proteasome inhibition is responsible for caspase activation and NF- κ B downregulation. We reported previously that a double bond between carbon 9 (C₉) and carbon 10 (C₁₀) in GA structure is the major chemical structure required for GA-induced proteasome inhibition¹⁹. In the current study, a C₉-C₁₀-disrupted GA (GA \sim) was used to compare with GA. As shown in Figure 3E, GA \sim (0.5 μ M) lost its ability to induce proteasome inhibition, caspase activation, apoptosis and NF- κ B downregulation, compared with GA treatment in SU-DHL-2 cells. These results show that GA-mediated proteasome inhibition is responsible for GA-induced caspase activation.

GA downregulates the protein levels of cell growth related signaling pathway. As signal transduction pathways including the MAPK/ERK cascade, PI3K/Akt, and STATs are generally considered to promote tumor cell growth^{24–26}, we also investigated the effect of GA on the protein expression of these signaling pathways in SU-DHL-4 and SU-DHL-2 cells. The phosphorylation of AKT, Erk1/2 and Stat5 were significantly decreased in a dose- and time-dependent manner with a less dramatic change in the total expression of Erk1/2 (Figure 4), indicating that GA suppress major cell growth signaling pathways, corroborating the data shown in Figure 1A and B in demonstrating an inhibitory effect of GA on DLBCL cell proliferation.

GA restrains the growth of xenografted GCB- and ABC-DLBCL cells in nude mice. We next evaluated the *in vivo* effects of GA using a nude mouse xenograft model. In the *in vivo* model, SU-DHL-4 and SU-DHL-2 cells were inoculated subcutaneously in nude mice. Mice were then treated by *i.p* injection with vehicle or GA (3 mg/kg/2d) for 13 days. It was found that GA treatment significantly inhibited the growth of both GCB- and ABC-DLBCL xenografts; the weights of tumors were significantly reduced in GA-treated group compared to the vehicle-treated (Figs. 5A and B), while body weight remained relatively stable in each group (data not shown). Protein levels including Akt, Erk1/2, Stat5 (Figure 5C) and the p65 subunit of NF- κ B proteins (Figure 5D) were significantly decreased in the




Figure 1 | GA induces apoptosis in both GCB- and ABC-DLBCL cells. (A) GA decreases cell viability of SU-DHL-4 and SU-DHL-2 cells. SU-DHL-4 and SU-DHL-2 cells exposed to GA in various concentrations for 48 hours were subjected to MTS assay. Graphs represent data from three repeats. Mean \pm SD ($n = 3$). (B) GA treatment inhibits cell proliferation in both GCB- and ABC-DLBCL cells. SU-DHL-4 and SU-DHL-2 cells grown in 24-well plates were treated with GA in various concentrations for 6, 12 or 24 hours. Total cell number was detected by trypan blue exclusion staining. Mean \pm SD ($n = 3$). (C) GA induces cell death in GCB- and ABC-DLBCL cells. SU-DHL-4 and SU-DHL-2 cells were treated with different doses of GA for 24 hours, then propidium iodide (PI) was added to the culture medium and the PI-positive cells were recorded under an inverted fluorescence microscope. Representative images were shown. (D) GA induces apoptosis in GCB- and ABC-DLBCL cells. SU-DHL-4 and SU-DHL-2 cells were treated with GA at the indicated doses for 24 hours and apoptosis was detected using Annexin V-FITC/PI double staining with flow cytometry. Representative images (left) and pooled data (right, mean \pm SD, $n = 3$) were shown.

GA-treated tumors, while proteasome target protein I κ B- α and the ubiquitinated proteins were highly accumulated in GA-treated tumors *versus* the control (Figure 5D), indicating that GA inhibits proteasome function in both GCB- and ABC-DLBCL xenografts. Together, the results demonstrate that GA inhibits both xenografted GCB- and ABC-DLBCL cells *in vivo*.

Discussion

DLBCL can be classified into three distinct subtypes (ABC-, GCB- and PMBCL- types) *via* gene expression profiling²⁻⁴. Improvements in DLBCL treatment, such as the introduction of R-CHOP therapy program⁸, have gradually appeared. Unfortunately, resistance to R-CHOP therapy and other current treatment regimens develops over




Figure 2 | GA-induced apoptosis is associated with caspase activation and decreased expression of anti-apoptotic proteins in both GCB- and ABC-DLBCL cells. (A) GA induces cleavage of PARP and caspase-3, -8, -9 in SU-DHL-4 and SU-DHL-2 cells. Cells were treated with GA at the indicated dose for the indicated time, PARP and caspase-3, -8, -9 cleavage were analyzed with western blots. Actin was used as a loading control. C: control. (B) GA induces down-regulation of mitochondrial membrane potential in SU-DHL-4 and SU-DHL-2 cells. Cells were treated with 0.25, 0.5 and 0.75 μM GA for 24 hours, mitochondrial membrane potential was detected using rhodamine-123 staining coupled with flow cytometry, mean \pm SD (n = 3). (C) GA induces AIF and cytochrome C release. SU-DHL-4 and SU-DHL-2 cells were exposed to GA for 1, 3 or 6 hours; then the cytosolic and mitochondrial fraction were extracted by digitonin buffer and Mitochondria Isolation Kit, respectively, and AIF and cytochrome C were detected with western blot analyses. Cox-4 was used as a loading control for the mitochondrial fraction. (C: cytosolic fraction; M: mitochondrial fraction.) (D) GA decreases the expression of anti-apoptotic proteins in SU-DHL-4 and SU-DHL-2 cells. Cells were dose- and time-dependently treated with GA. The anti-apoptotic proteins Mcl-1, XIAP, Bcl-2, survivin and pro-apoptotic protein Bax were analyzed by western blot. (E) GA decreases XIAP in a caspase-dependent manner. SU-DHL-2 cells were treated with 0.5 μM GA with or without caspase inhibitor z-VAD-fmk (20 μM) for 12 hours. The Mcl-1 and XIAP proteins were detected using western blot analyses.




Figure 3 | GA inhibits proteasome function in SU-DHL-4 and SU-DHL-2 cells. (A) GA inhibits proteasome peptidase activities in SU-DHL-4 and SU-DHL-2 cells. The cells were treated with GA at 37°C for 6 hours, followed by detecting CT-like activity with a Cell-Based Assay Reagent. Mean \pm SD ($n = 3$). (B) GA accumulates proteasome substrate proteins in SU-DHL-4 and SU-DHL-2 cells. Cells were treated with GA at the indicated dose for the indicated time. The protein levels of PARP, ubiquitinated proteins (Ubs), p27 and p21 were detected with western blot analyses. Actin was used as a loading control. C: control. (C) GA up-regulates the expression of I κ B α and decreases the protein levels of p65 subunit of NF- κ B and its target proteins including IAP-1, IAP-2, Bcl-x and Bfl-1. SU-DHL-4 and SU-DHL-2 cells were treated with GA at the indicated dose for the indicated time. Western blot analyses were performed for detecting total and phosphorylated p65 and I κ B α , as well as IAP-1, IAP-2, Bcl-x and Bfl-1. (D) GA and PS341 do not decrease the nuclear translocation of p65. SU-DHL-2 cells were treated with 0.25, 0.5, 0.75 μ M GA and PS341 (50 nM) for 4 hours, cytoplasmic and nuclear proteins were extracted. Western blot analyses were performed for detection of the indicated proteins. Actin and PCNA were used as cytoplasm and nuclear protein loading controls, respectively. (E) GA-mediated proteasome inhibition is the major cause of either caspase activation or NF- κ B downregulation. SU-DHL-2 cells were treated with GA (0.5 μ M) for 12 hours and a C9-C10-disrupted GA (GA \sim) was used as a negative control. Western blot analyses were performed for detection of the indicated proteins. Actin was used as a loading control.

time and is an emerging problem for DLBCL treatment^{9–11}. Particularly, ABC-DLBCL, characterized by increased dependence on the NF- κ B pathway, has poorer overall survival than the GCB-DLBCL counterpart⁷. Therefore, innovative therapeutic strategies for DLBCL patients, especially the ABC-DLBCL patients, are critically warranted.

GA, the major active component in the traditional Chinese medicine gamboge, has antitumor activities in a broad range of human cancer cells^{13,14}. The results of the present study indicate that GA dramatically induces cytotoxicity in DLBCL cells, including both ABC- and GCB-DLBCL. In the cell culture experiments, GA dose- and time-dependently decreased cell viability, cell proliferation and




Figure 4 | GA decreases the signaling protein levels of the cell growth related pathway, such as AKT, Erk1/2 and STAT5. SU-DHL-4 and SU-DHL-2 cells were treated with GA at the indicated dose for the indicated time. Cell lysates were analyzed using western blot. C: control.




Figure 5 | GA inhibits tumor growth in both GCB- and ABC-DLBCL xenografted mouse models. Nude BALB/c mice bearing SU-DHL-4 and SU-DHL-2 cells were randomized to vehicle- and GA (3 mg/kg/2d)-treatment group. Treatment was initiated when the average tumor size reached 50 mm³. (A) Tumor volume was recorded every day after treatment. Mean \pm SD (n = 6). ** P < 0.01, *** P < 0.001. (B) On day 13 after inoculation, the mice were sacrificed and the tumor tissues were weighed and imaged. *** P < 0.001 vs. the control group. (C) Cell growth related pathway in tumor tissues were detected with western blot analyses (SU-DHL-4 control group: 1, 3; GA-treated group: 8, 10; SU-DHL-2 control group: 13, 16; GA-treated group: 20, 24.) (D) Immunohistochemistry analyses were performed to examine ubiquitinated proteins, I κ B- α , and P65 in the tumor tissues. All the immunostaining and western blot analyses were repeated in three mouse tumor tissues and the representative images are shown.



induced cell death in both ABC- and GCB-DLBCL cell lines; in the *in vivo* experiment, both ABC- and GCB-DLBCL xenografted tumors were all sensitive to GA treatment. To our knowledge, this is the first report to show that GA is effective against DLBCL cells, including ABC-DLBCL cells.

Proteasome inhibitors such as carfilzomib have been reported to induce cell death in DLBCL cells²⁰; however, the role of GA in DLBCL was not reported. Recently we have reported that GA is a tissue-specific proteasome inhibitor with low toxicity¹⁹. In the current study we discovered a pathway that GA-mediated proteasome inhibition and caspase activation is responsible for GA-induced cytotoxicity in DLBCL cells. Like in other cancer cells^{19,44}, GA induced typical proteasome inhibition in both ABC- and GCB-DLBCL cells *in vitro* and *in vivo*. We have reported that proteasome inhibition-induced Bax accumulation plays an important role in proteasome inhibition-mediated caspase activation and cell apoptosis²⁷. Here we found that GA induced Bax accumulation while anti-apoptotic proteins such as XIAP and Survivin were significantly decreased in a dose- and time-dependent manner. The imbalance between pro-apoptotic and anti-apoptotic factors led to the decrease of mitochondrial membrane integrity, thereby inducing the release of cytochrome C and AIF. The released apoptotic factors either directly or by forming a caspase-9 complex, induced caspase activation (Figure 2).

By proteasome inhibition, GA on one hand may induce caspase activation and then apoptosis; on the other hand, it may interfere with the degradation of I κ B α and thereby prevents the activation of NF- κ B. Normally, without stimulation, NF- κ B binds with I κ B α , an important substrate protein in cytoplasm. With the extra- or intracellular stimulation, I κ B α is phosphorylated and degraded by the ubiquitin-proteasome system, which frees out NF- κ B in cytoplasm and allows its translocation into the nucleus to regulate cell survival and cell death^{28–30}. To determine whether caspase activation is required for GA to downregulate anti-apoptotic proteins, cells were treated with GA (0.5 μ M) for 12 hours in the absence or presence of z-VAD, then both XIAP (IAP family) and Mcl-1 (Bcl-2 family) proteins were detected by western blot. It was found that GA could decrease XIAP levels but increase Mcl-1 levels at the dose of 0.5 μ M for 12 hours. XIAP decrease by GA was nearly completely recovered in the presence of a pan-caspase inhibitor z-VAD. Once the cells were treated with GA for more than 24 hours, Mcl-1 was also decreased, but the decrease could only be partially reversed by z-VAD (data not shown), consistent with a previous report³¹. These results suggest that the decrease of XIAP by GA depends primarily on the presence of caspase activation, inferring that transcriptional mechanisms mediated by pathways such as the NF- κ B pathway may not play a significant role here.

To further clarify whether GA-mediated decreases of several other proteins depend suppression of the NF- κ B pathway, we further detected the mRNA levels of several other target genes of the NF- κ B pathway including IAP family members (IAP-1, IAP-2) and Bcl-2 family members (Bcl-x and Bfl-1). Surprisingly, we did not detect any obvious decreases in the mRNA expression after GA treatment (Supplementary Figure), suggesting that GA treatment induced downregulation of these proteins occurs as result of post-transcriptional mechanisms. Based on these results, the decrease of survivin at low dose of GA treatment or at short time point is probably not caused by a decrease in NF- κ B activity as survivin is also a member of the IAP family. Moreover, we compared the effect of various doses of GA on NF- κ B nuclear translocation with that of a classical proteasome inhibitor PS341. As shown in Figure 3D, low dose of GA (0.25 μ M) did show the tendency to block the NF- κ B nuclear translocation, but the other doses of GA as well as PS341 could not block the nuclear translocation of NF- κ B. Taken together, our data suggest that inhibition of the NF- κ B pathway does not appear to be a major mechanism for GA to induce apoptosis, contradictory to part of our original hypothesis.

Because of the critical role of the NF- κ B signaling pathway, a previous report investigated the effects of GA on NF- κ B-mediated cellular responses and NF- κ B-regulated gene products in human leukemia cells. Treating the cells with GA enhanced apoptosis induced by tumor necrosis factor (TNF) and chemotherapeutic agents, and inhibited the expression of gene products involved in antiapoptosis (IAP-1 and IAP-2, Bcl-2, Bcl-x_L, and TRAF1), cell proliferation (cyclin D1 and c-Myc), invasion (COX-2 and MMP-9), and angiogenesis (VEGF), all of which are known to be regulated by NF- κ B³². However, in that report, they did not detect the mRNA expression after GA treatment alone. Here, our present study is the first time to report that GA did not downregulate mRNA expression of these NF- κ B target genes in the cell lines tested here.

Our data show that GA accumulated Mcl-1 protein in the cell in the case of low dose of GA or short-time treatment, in agreement with what previously reported for other proteasome inhibitor treatment³³. Mcl-1 protein degradation is mediated by proteasome- and/or caspase-dependent mechanisms. Both processes rapidly decrease its cellular level^{34,35}. It has been reported that Mcl-1 strongly determines the effectiveness of bortezomib, a classical proteasome inhibitor. Mcl-1 accumulated in CD34 (+) AML cells upon bortezomib treatment and inhibition of Mcl-1 by shRNA significantly improved the sensitivity of CD34 (+) AML cells to bortezomib. These results suggest that combining bortezomib with specific Mcl-1 inhibitors might potentially target the leukemic stem cells³⁶. In our current study, one reason for Mcl-1 accumulation is likely its degradation inhibition mediated by GA-induced proteasome inhibition. Another possible reason is related to GA-mediated unfolded protein response (UPR). We have also previously reported that GA could induce UPR¹⁹. It was recently reported that Mcl-1 accumulation could be induced by the UPR, where the translation of activating transcription factor-4 (ATF4), an important effector of the UPR, was greatly enhanced by proteasome inhibition. ChIP analysis further revealed that bortezomib stimulated binding of ATF4 to a regulatory site (at position -332 to -324) at the promoter of the Mcl-1 gene. Knocking down ATF4 resulted in down-regulation of Mcl-1 in bortezomib-treated cells and significantly increased bortezomib-induced apoptosis. These studies identify the UPR and more specifically, its ATF4 branch as an important mechanism mediating up-regulation of Mcl-1 by proteasome inhibition³⁷.

Notably, although Mcl-1 accumulation attenuates the pro-apoptotic effect of bortezomib, it is probably cannot do so to GA. Based on our results, GA efficiently induced cell death in these two cell lines even in the presence of Mcl-1 accumulation. This is possibly due to the direct effect of GA on Bcl-2 family proteins, in contrast to bortezomib which does not have such effect. It has been reported by others that suppression of antiapoptotic Bcl-2 family proteins may be a cytotoxic mechanism by which GA kills tumor cells. Using the anti-apoptotic Bcl-2 family protein, Bfl-1, as a target for screening of a library of natural products, GA was identified as a competitive inhibitor that displaced BH3 peptides from Bfl-1. Analysis of competition for BH3 peptide binding revealed that GA inhibits all six human Bcl-2 family proteins to various extents, with Mcl-1 being most potently inhibited³⁸. Hence, GA may be more potent and optimal than conventional proteasome inhibitor (eg, bortezomib) to kill cancer cells considering the important role of Mcl-1 in cell survival.

PI3K/AKT, Raf/Erk and Jak/STAT signal pathways are shown constitutive activation in many tumors, contributing to uncontrolled tumor cell growth^{24–26,30,39,40}. Our results showed that GA induced decreases in the phosphorylation status of AKT, Erk1/2 and STAT5 (Figure 4), corroborating the impaired growth of GA-treated DLBCL cells (Figure 1A and 1B). The STAT5 enhancing survival of cancer cells involves the transcription of Mcl-1, survivin or XIAP^{41,42}. Treatment with GA resulted in downregulation of Mcl-1, survivin and XIAP (Figure 2D). Even though GA may impact on multiple molecules, downregulation of these signaling proteins is at least one



of the major factors to induce cell growth inhibition and apoptosis in DLBCL cells.

In summary, our findings collectively demonstrate that GA has a significant effect against the GCB and ABC subtypes of DLBCL cells *in vitro* and *in vivo*. Proteasome inhibition-induced caspase activation may chiefly contribute to GA-induced cytotoxicity in these cells. These findings suggest for the first time that GA may have clinical benefit for patients with DLBCL, particularly the patients with ABC subtypes DLBCL, which is of great importance in future exploration of clinical cancer therapy.

Methods

Chemicals. GA, diethyl dithiocarbamate (DDC), Annexin V, propidium iodide (PI) and rhodamine-123 were obtained from Sigma-Aldrich (St. Louis, MO). Mitochondria Isolation Kit was obtained from Thermo Scientific (TMO, USA). C₉-C₁₀ disrupted GA (GA~) was synthesized by our laboratory¹⁹. Antibodies (Abs) against Mcl-1 (S-19), ubiquitin (P4D1), caspase-3, -8, -9, apoptosis-inducing factor (AIF), P27, P21, Bcl-2 and Bax were from Santa Cruz Biotechnology (Santa Cruz, CA). Abs against poly (ADP-ribose polymerase (PARP, clone 4C10-5) was from BD Biosciences. Abs against p65, phospho-p65 at Ser536, inhibitor of kappa B α (I κ B α), phospho-I κ B α at Ser32, phospho-Erk1/2 (T202/Y204), Erk1/2, phospho-Akt, Akt, I κ B- α , cleaved caspase-3, -9, cytochrome C, Survivin, XIAP, IAP-1, IAP-2, Bcl-x and Bfl-1 were from Cell Signaling Technology (Beverly, MA, USA). Abs against phospho-Stat5A/B (Y694/Y699, clone 8-5-2) and Stat5 were from Upstate Technology; mouse monoclonal antibody against Actin, Cox-4 and PCAN from Sigma-Aldrich. Enhanced chemiluminescence reagents were purchased from Amersham Biosciences (Piscataway, NJ, USA).

Cell culture. The DLBCL cell line SU-DHL-4 (GCB-DLBCL) and SU-DHL-2 (ABC-DLBCL) cells were purchased from ATCC and incubated in RPMI 1640 medium (Life Technologies) supplemented with 10% fetal calf serum (Hyclone), 1 unit/ml penicillin, and 1 μ g/ml streptomycin. Cells were incubated at 37°C and in water vapor-saturated air with 5% CO₂ at one atmospheric pressure.

Preparation of cell fractions and western blot analysis. Whole cell lysates were prepared in RIPA buffer²¹ (1 \times PBS, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS) supplemented with 10 mM β -glycerophosphate, 1 mM sodium orthovanadate, 10 mM NaF, 1 mM phenylmethylsulfonyl fluoride (PMSF), and 1 \times Roche Protease Inhibitor Cocktail (Roche, Indianapolis, IN). To detect the level of cytochrome C, AIF and NF- κ B nucleus translocation, the cytosolic fraction was prepared with a digitonin extraction buffer (10 mM PIPES, 0.015% digitonin, 300 mM sucrose, 100 mM NaCl, 3 mM MgCl₂, 5 mM EDTA, and 1 mM PMSF), and the nuclear protein was prepared with extraction buffer with inhibitors (20 mM Hepes, pH 7.9, 0.4 M NaCl, 1 mM EDTA with 1 mM DTT, 0.5 mM PMSF, 1 mM NaF and 1 mM Complete Protease Inhibitor Mix) as described previously⁴³. To detect the level of mitochondrial cytochrome C and AIF, cells were extracted with Thermo Scientific Mitochondria Isolation Kit using the reagent-based method. The mitochondrial fractions were prepared in RIPA buffer supplemented with 10 mM NaF, 1 mM PMSF, and 1 \times Roche Protease Inhibitor Cocktail. Western blotting was performed as we previously described^{43,44}.

Cell viability assay. MTS assay (CellTiter 96 Aqueous One Solution reagent, Promega) was used to measure cell viability⁴⁵. Briefly, 2 \times 10⁵/ml cells in 100 μ l were treated with GA for 48 hours. Control cells received DMSO for a final concentration the same as the highest concentration of GA but less than 0.1%v/v. 4 hours before culture termination, 20 μ l MTS was added to the wells. The absorbance density was read on a 96-well plate reader at wavelength 490 nm.

Cell counting assay. SU-DHL-4 and SU-DHL-2 cells were seeded into 24-well plates (2 \times 105/ml, 1 ml/well) and treated with GA in various concentrations for indicated duration, then 0.4% trypan blue (Sigma-Aldrich) was added to count the number of live and dead cells under a light microscope.

Cell death assay. 1.0% PI was added to the culture medium to monitor temporal changes in the incidence of cell death in the live culture condition. The PI-positive cells were imaged with an epi-fluorescence microscope equipped with a digital camera (Axio Observer Z1, Zeiss, Germany)⁴⁵. Cell apoptosis was determined by flow cytometry using Annexin V-fluoroisothiocyanate (FITC)/PI double staining⁴³. SU-DHL-4 and SU-DHL-2 cells were collected, washed with binding buffer (Sigma-Aldrich, St. Louis, MO), and then incubated in working solution (100 μ l binding buffer with 0.3 μ l Annexin V-FITC and PI) for 15 minutes in dark.

Measurement of mitochondrial membrane integrity. The mitochondrial membrane potential of GA-treated and untreated cells were assayed by using rhodamine-123 (Sigma-Aldrich, St. Louis, MO) staining. Cells were treated with various concentrations of GA for 24 hours and stained with 1 μ M of rhodamine-123 for 1 hour at 37°C. Following the staining, the cells were washed and harvested for either flow cytometry analysis or imaging with an inverted fluorescence microscope.

Chymotrypsin-like (CT-like) peptidase activity assay. About 4,000 SU-DHL-4 and SU-DHL-2 cells were treated with GA for 6 hours. The cells were then incubated with the Glo Cell-Based Assay Reagent (Promega Bioscience, Madison, WI) for 10 minutes⁴⁵. The proteasomal CT-like activity was detected as the relative light unit (RLU) generated from the cleaved substrate. Luminescence generated from each reaction was detected with luminescence microplate reader (Varioskan Flash 3001, Thermo, USA).

RNA isolation and real-time quantitative polymerase chain reaction (PCR). Total RNA was extracted from 5 \times 10⁶ cells by use of Trizol reagent (Invitrogen). After quantification by spectrophotometry, the first-strand cDNA was synthesized from 500 ng of total RNA with the use of the RNA PCR Kit (AMV) Ver.3.0 (TaKaRa, Dalian, China) and random primers. Then 50 ng of total cDNA was used for real-time PCR with the SYBR Premix Ex TaqII Kit (TaKaRa). The reaction used the ABI 7500 Real-Time PCR System. The relative gene expression was analyzed by the Comparative Ct method using 18 S ribosomal RNA as endogenous control, after confirming that the efficiencies of the target and the endogenous control amplifications were approximately equal. The specific primers for real-time PCR are as follows: IAP-1 forward, 5'-AAC ATG CCA AGT GGT TTC CAA-3'; IAP-1 reverse, 5'-TGA AGA ACT TTC TCC AGG TCC AA-3'; IAP-2 forward, 5'-AAG CCA GTT ACC CTC ATC TAC TTG-3'; IAP-2 reverse, 5'-GCT TCT ACT AAA GCC CAT TTC CA-3'; Bcl-x forward, 5'-CTG GCT CCC ATG ACC ATA CTG A-3'; Bcl-x reverse, 5'-GTG AGG CAG CTG AGG CCA TAA-3'; Bfl-1 forward, 5'-TCC GTA GAC ACT GCC AGA ACA C-3'; Bfl-1 reverse, 5'-CTC CGT TTT GCC TTA TCC ATT C-3'; 18 s forward, 5'-AAA CGG CTA CCA CAT CCA AG-3'; 18 s reverse, 5'-CCT CCA ATG GAT CCT CGT TA-3'.

Nude mouse xenograft model. Nude Balb/c mice were bred at the animal facility of Guangzhou Medical College. The mice were housed in barrier facilities with a 12 hours light dark cycle, with food and water available ad libitum. 3 \times 10⁷ of SU-DHL-4 and SU-DHL-2 cells were inoculated subcutaneously on the flanks of 5-week-old male nude mice. After 5–6 days of inoculation, mice were treated with either vehicle (10% DMSO, 30% cremophor and 60% NaCl) and GA (3 mg/kg/2 d) for totally 13 days. Tumors were measured and tumor volumes were calculated by the following formula: $a^2 \times b \times 0.4$, where a is the smallest diameter and b is the diameter perpendicular to a . At day 13 after treatment, tumor xenografts were removed, weighed, stored and fixed. All experiments were performed in accordance with relevant guidelines and regulations. All animal studies were conducted with the approval of the Institutional Animal Care and Use Committee of Guangzhou Medical University.

Statistical analysis. All experiments were performed at least thrice, and the results were expressed as mean \pm SD where applicable. GraphPad Prism 4.0 software (GraphPad Software) was used for statistical analysis. Comparison of multiple groups was made with one-way ANOVA followed by Tukey's test or Newman-Kuels test. P value of < 0.05 was considered statistically significant.

1. Coiffier, B. Immunotherapy: the new standard in aggressive non-Hodgkin's lymphoma in the elderly. *Semin Oncol* **30**, 21 (2003).
2. Alizadeh, A. A. *et al.* Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. *Nature* **403**, 503 (2000).
3. Rosenwald, A. *et al.* The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. *N Engl J Med* **346**, 1937 (2002).
4. Lenz, G. *et al.* Stromal gene signatures in large-B-cell lymphomas. *N Engl J Med* **359**, 2313 (2008).
5. Gronbaek, K. & Jaattela, M. Engaging the lysosomal compartment to combat B cell malignancies. *J Clin Invest* **119**, 2133 (2009).
6. Bosch, R. *et al.* A novel inhibitor of focal adhesion signaling induces caspase-independent cell death in diffuse large B-cell lymphoma. *Blood* **118**, 4411 (2011).
7. Rosenwald, A. *et al.* Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. *J Exp Med* **198**, 851 (2003).
8. Coiffier, B. *et al.* CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. *N Engl J Med* **346**, 235 (2002).
9. Winter, J. N. *et al.* Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. *Blood* **107**, 4207 (2006).
10. Richardson, P. G. *et al.* A phase 2 study of bortezomib in relapsed, refractory myeloma. *N Engl J Med* **348**, 2609 (2003).
11. Cvetkovic, R. S. & Perry, C. M. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. *Drugs* **66**, 791 (2006).
12. Zhang, H. Z. *et al.* Discovery and SAR of indole-2-carboxylic acid benzylidenehydrazides as a new series of potent apoptosis inducers using a cell-based HTS assay. *Bioorg Med Chem* **12**, 3649 (2004).
13. Guo, Q. L. *et al.* Inhibition of human telomerase reverse transcriptase gene expression by gambogic acid in human hepatoma SMMC-7721 cells. *Life Sci* **78**, 1238 (2006).
14. Liu, W. *et al.* Anticancer effect and apoptosis induction of gambogic acid in human gastric cancer line BGC-823. *World J Gastroenterol* **11**, 3655 (2005).



15. Chuah, L. O. *et al.* In vitro and in vivo toxicity of garcinia or hydroxycitric Acid: a review. *Evid Based Complement Alternat Med* **2012**, 197920 (2012).
16. Marquez, F., Babio, N., Bullo, M. & Salas-Salvado, J. Evaluation of the safety and efficacy of hydroxycitric acid or Garcinia cambogia extracts in humans. *Crit Rev Food Sci Nutr* **52**, 585 (2012).
17. Zhao, L. *et al.* Gambogic acid induces apoptosis and regulates expressions of Bax and Bcl-2 protein in human gastric carcinoma MGC-803 cells. *Biol Pharm Bull* **27**, 998 (2004).
18. Palempalli, U. D. *et al.* Gambogic acid covalently modifies IkappaB kinase-beta subunit to mediate suppression of lipopolysaccharide-induced activation of NF-kappaB in macrophages. *Biochem J* **419**, 401 (2009).
19. Li, X. *et al.* Gambogic acid is a tissue-specific proteasome inhibitor in vitro and in vivo. *Cell Rep* **3**, 211 (2013).
20. Dasmahapatra, G. *et al.* The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo. *Blood* **115**, 4478 (2010).
21. Davis, R. E., Brown, K. D., Siebenlist, U. & Staudt, L. M. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. *J Exp Med* **194**, 1861 (2001).
22. Hisatomi, T. *et al.* The regulatory roles of apoptosis-inducing factor in the formation and regression processes of ocular neovascularization. *Am J Pathol* **181**, 53 (2012).
23. Laszlo, C. F. & Wu, S. Old target new approach: an alternate NF-kappaB activation pathway via translation inhibition. *Mol Cell Biochem* **328**, 9 (2009).
24. Garrington, T. P. & Johnson, G. L. Organization and regulation of mitogen-activated protein kinase signaling pathways. *Curr Opin Cell Biol* **11**, 211 (1999).
25. Franke, T. F. PI3K/Akt: getting it right matters. *Oncogene* **27**, 6473 (2008).
26. Steelman, L. S. *et al.* Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia. *Leukemia* **22**, 686 (2008).
27. Li, B. & Dou, Q. P. Bax degradation by the ubiquitin/proteasome-dependent pathway: involvement in tumor survival and progression. *Proc Natl Acad Sci USA* **97**, 3850 (2000).
28. Malek, S., Chen, Y., Huxford, T. & Ghosh, G. IkappaBbeta, but not IkappaBalpha, functions as a classical cytoplasmic inhibitor of NF-kappaB dimers by masking both NF-kappaB nuclear localization sequences in resting cells. *J Biol Chem* **276**, 45225 (2001).
29. Malek, S. *et al.* X-ray crystal structure of an IkappaBbeta x NF-kappaB p65 homodimer complex. *J Biol Chem* **278**, 23094 (2003).
30. Dolcet, X., Llobet, D., Pallares, J. & Matias-Guiu, X. NF-kB in development and progression of human cancer. *Virchows Arch* **446**, 475 (2005).
31. Nencioni, A. *et al.* Evidence for a protective role of Mcl-1 in proteasome inhibitor-induced apoptosis. *Blood* **105**, 3255 (2005).
32. Pandey, M. K. *et al.* Gambogic acid, a novel ligand for transferrin receptor, potentiates TNF-induced apoptosis through modulation of the nuclear factor-kappaB signaling pathway. *Blood* **110**, 3517 (2007).
33. Podar, K. *et al.* A pivotal role for Mcl-1 in Bortezomib-induced apoptosis. *Oncogene* **27**, 721 (2008).
34. Michels, J. *et al.* Mcl-1 is required for Akata6 B-lymphoma cell survival and is converted to a cell death molecule by efficient caspase-mediated cleavage. *Oncogene* **23**, 4818 (2004).
35. Zhong, Q., Gao, W., Du, F. & Wang, X. Mule/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiquitination of Mcl-1 and regulates apoptosis. *Cell* **121**, 1085 (2005).
36. Bosman, M. C., Schuringa, J. J., Quax, W. J. & Vellenga, E. Bortezomib sensitivity of acute myeloid leukemia CD34(+) cells can be enhanced by targeting the persisting activity of NF-kappaB and the accumulation of MCL-1. *Exp Hematol* **41**, 530 (2013).
37. Hu, J. *et al.* Activation of ATF4 mediates unwanted Mcl-1 accumulation by proteasome inhibition. *Blood* **119**, 826 (2012).
38. Zhai, D. *et al.* Gambogic acid is an antagonist of antiapoptotic Bcl-2 family proteins. *Mol Cancer Ther* **7**, 1639 (2008).
39. Manning, B. D. & Cantley, L. C. AKT/PKB signaling: navigating downstream. *Cell* **129**, 1261 (2007).
40. Steelman, L. S. *et al.* Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy. *Leukemia* **25**, 1080 (2011).
41. Nelson, E. A. *et al.* The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors. *Blood* **117**, 3421 (2011).
42. Warsch, W. *et al.* High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia. *Blood* **117**, 3409 (2011).
43. Shi, X. *et al.* Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation. *Clin Cancer Res* **15**, 1686 (2009).
44. Shi, X. *et al.* Gambogic acid induces apoptosis in imatinib-resistant chronic myeloid leukemia cells via inducing proteasome inhibition and caspase-dependent Bcr-Abl downregulation. *Clin Cancer Res* **20**, 151 (2014).
45. Huang, H. *et al.* Physiological levels of ATP negatively regulate proteasome function. *Cell Res* **20**, 1372 (2010).

Acknowledgments

This work was supported by the National High Technology Research and Development Program of China (2006AA02Z4B5); NSFC (81272451/H1609, 81472762/H1609) (to J.L.); NSFC (81100378/H0812, 81470355/H1616, 81272556/H1612) (to X.S.); partially supported by US NIH grants HL072166 and HL085629 (to X.W.).

Author contributions

X.S., X.L., C.Z., X.C., X.F.L., S.L., H.H., N.L., D.Z., Y.L. and P.Z. planned most of the *in vitro* experiments; X.S., X.L. and H.H. performed the *in vivo* experiments; J.L., X.S. and X.W. conceived of the study, analyzed data and wrote the manuscript. All authors reviewed the manuscript.

Additional information

Supplementary information accompanies this paper at <http://www.nature.com/scientificreports>

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Shi, X. *et al.* Gambogic acid induces apoptosis in diffuse large B-cell lymphoma cells via inducing proteasome inhibition. *Sci. Rep.* **5**, 9694; DOI:10.1038/srep09694 (2015).



This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder in order to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>